Vivus stays at outperform by RBC

Vivus Inc. was reiterated at outperform, speculative risk, with a $6 price target by RBC Capital Markets analyst Ken Trbovich following a conference call with the Onexa phase 2 trial lead investigator. There is confidence that phase 2 results would be easily repeatable in a phase 3 trial. The only reservation is that the study was not large enough to detect very small rates of serious adverse events, according to the analyst. Shares of the Mountain View, Calif.-based pharmaceutical company were up 12 cents, or 3.12%, at $3.97 on volume of 394,690 shares versus the three-month running average of 290,345 shares. (Nasdaq: VVUS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.